Alt image -https://content.stockstotrade.com/wp-content/uploads/2026/10/boston-scientific-falls-13-after-cybersecurity-outlook-cut.webp

Boston Scientific Falls 4% After Cutting Outlook

TIM BOHEN•UPDATED OCT. 28, 2026, 2:02 PM ET
Reviewed by Ben Sturgilland Fact-checked by Jack Kellogg

Boston Scientific fell 4% after lowering its outlook as cyberattack fallout and weak heart-device sales extended pressure into next quarter.

BSX Candlestick Chart

Get Free Alerts

Why Boston Scientific Stock Fell Today

Boston Scientific is down 4% at $43.26 by early afternoon after cutting its full-year outlook. Its quarterly results beat analyst estimates, but the lower forecast points to more pressure on future sales and profit. The company said a cybersecurity incident, a cyberattack that disrupted operations, will affect results into next quarter.

What Boston Scientific Corporation Does

Boston Scientific makes medical devices for heart care and other medical procedures. It sells products that doctors and hospitals use to treat patients, so disruptions to its operations can affect sales and service.

Boston Scientific Third-Quarter Earnings

Adjusted earnings per share, profit allocated to each share after certain items are removed, came in above analyst estimates. Revenue also beat estimates, but those results describe the quarter just reported, not the outlook for coming months.

Boston Scientific Full-Year Guidance

Guidance, the company’s forecast for future results, now calls for slower sales growth and lower adjusted earnings for the year. Its next-quarter adjusted earnings forecast is also below the average analyst estimate. Slower expected growth gives investors less reason to pay as much for the shares.

Boston Scientific Watchman And Electrophysiology

Watchman, the company’s heart-device business, and electrophysiology, which diagnoses and treats heart-rhythm problems, both weakened. Their slower growth adds pressure beyond the cyber disruption and makes a quick return to stronger sales less certain.

Quick Financial Overview

Boston Scientific is a large-cap, meaning one of the larger publicly traded companies. It is profitable, with $62.70B in market value, the total worth of its shares. Its latest financial snapshot lists $539.0M in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026.

Boston Scientific Revenue And Earnings

The same quarterly financial snapshot showed $5.44B in revenue and net income of $907.0M. The positive net income means the company earned more than it spent under its accounting rules during that period.

Get Free Alerts

Boston Scientific Stock down 59% Over Past Year

Boston Scientific stock is down 59% over the past year, putting today’s drop within a longer decline. Shares reached a high near $45 in premarket trading, meaning before regular trading began, then gave back much of that rebound. For this stock, the last daily move this large was thirty-two sessions ago.

Trading Perspective

The past year’s high at the $110 level is the longer-range level above the stock. Today’s opening gap, the price break between sessions, bottoms at the $40 level. That does not mean buying will stop another decline there.

Boston Scientific Trading Volume Today

Trading reached about 41 million shares, running at about four times the usual pace for this hour. That heavier activity shows today’s price drop drew more trading than usual, though it does not establish how long the reaction will last.

Get Free Alerts

Conclusion

Boston Scientific’s next quarterly earnings report is the next checkpoint, though its date is not yet known. Stronger sales and heart-device demand would show the pressure is easing, while continued weakness would point to a longer recovery.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.


The Game is Rigged

But Our AI-driven analysis Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – and join 10,000+ traders